Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily K Sims

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
Molecular Metabolism|September 11, 2019
Cause or effect? A review of clinical data demonstrating beta cell dysfunction prior to the clinical onset of type 1 diabetesEmily K Sims, Linda A DiMeglio
Molecular Endocrinology (Baltimore, Md.)|September 23, 2015
Minireview: Emerging Roles for Extracellular Vesicles in Diabetes and Related Metabolic DisordersAlexander J Lakhter, Emily K Sims
The Journal of Clinical Endocrinology and Metabolism|June 8, 2023
Screening and Prevention of Type 1 Diabetes: Where Are We?Kimber M Simmons, Emily K Sims
Islets|May 10, 2021
Not so sweet and simple: impacts of SARS-CoV-2 on the β cellSarah Ibrahim, Gabriela S F Monaco, Emily K Sims
Diabetologia|February 16, 2019
Beta cells in type 1 diabetes: mass and function; sleeping or dead?Richard A Oram, Emily K Sims, Carmella Evans-Molina
Clinical Pediatrics|August 27, 2011
Detours on the road to diagnosis of Graves diseaseEmily K Sims, Erica A Eugster, Todd D Nebesio
Current Opinion in Endocrinology, Diabetes, and Obesity|July 4, 2020
The role of beta-cell dysfunction in early type 1 diabetesEmily K Sims, Raghavendra G Mirmira, Carmella Evans-Molina
Diabetes|September 23, 2021
The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 DiabetesEmily K Sims, David Cuthbertson, Kevan C Herold, et al.
Current Diabetes Reports|August 20, 2016
Biomarkers of β-Cell Stress and Death in Type 1 DiabetesRaghavendra G Mirmira, Emily K Sims, Farooq Syed, et al.
Diabetologia|September 4, 2023
High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatmentEmily K Sims, Susan M Geyer, S Alice Long, et al.
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
Molecular Metabolism|September 11, 2019
Cause or effect? A review of clinical data demonstrating beta cell dysfunction prior to the clinical onset of type 1 diabetesEmily K Sims, Linda A DiMeglio
Molecular Endocrinology (Baltimore, Md.)|September 23, 2015
Minireview: Emerging Roles for Extracellular Vesicles in Diabetes and Related Metabolic DisordersAlexander J Lakhter, Emily K Sims
The Journal of Clinical Endocrinology and Metabolism|June 8, 2023
Screening and Prevention of Type 1 Diabetes: Where Are We?Kimber M Simmons, Emily K Sims
Islets|May 10, 2021
Not so sweet and simple: impacts of SARS-CoV-2 on the β cellSarah Ibrahim, Gabriela S F Monaco, Emily K Sims
Diabetologia|February 16, 2019
Beta cells in type 1 diabetes: mass and function; sleeping or dead?Richard A Oram, Emily K Sims, Carmella Evans-Molina
Clinical Pediatrics|August 27, 2011
Detours on the road to diagnosis of Graves diseaseEmily K Sims, Erica A Eugster, Todd D Nebesio
Current Opinion in Endocrinology, Diabetes, and Obesity|July 4, 2020
The role of beta-cell dysfunction in early type 1 diabetesEmily K Sims, Raghavendra G Mirmira, Carmella Evans-Molina
Diabetes|September 23, 2021
The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 DiabetesEmily K Sims, David Cuthbertson, Kevan C Herold, et al.
Current Diabetes Reports|August 20, 2016
Biomarkers of β-Cell Stress and Death in Type 1 DiabetesRaghavendra G Mirmira, Emily K Sims, Farooq Syed, et al.
Diabetologia|September 4, 2023
High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatmentEmily K Sims, Susan M Geyer, S Alice Long, et al.
Pageof 9